Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 8/20 | 0.35 |
| ▸ | WNT1 | P04628 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16120069 | 0.78 | PRMT1 (0.42) | NTRK1AXLCDK1CDK4CDK2 | |
| SCHEMBL16120068 | 0.73 | JAK2 (0.36) | NTRK1DYRK1ACDK1CDK4CDK2 | |
| SCHEMBL18789070 | 0.67 | LRRK2 (0.41) | DYRK1AFLT3 | |
| SCHEMBL17465774 | 0.66 | NTRK1 (0.41) | NTRK1AXLCDK1CDK4CDK2 | |
| SCHEMBL17457591 | 0.64 | NTRK1 (0.41) | NTRK1WNT1DYRK1AAXLCDK1 | |
| SCHEMBL16120044 | 0.61 | JAK2 (0.40) | NTRK1DYRK1ACDK1CDK4CDK2 | |
| SCHEMBL24172742 | 0.60 | JAK2 (0.45) | NTRK1WNT1DYRK1AAXLFGFR1 | |
| SCHEMBL14487030 | 0.59 | JAK2 (0.59) | NTRK1JAK2 | |
| SCHEMBL22537876 | 0.58 | ADRB1 (0.50) | — | |
| SCHEMBL2088906 | 0.57 | DYRK1A (0.65) | WNT1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | NTRK1 4653/4885WNT1 3932/4885DYRK1A 3883/4885 |
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | NTRK1 4653/4885WNT1 3932/4885DYRK1A 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.